Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AUA 2016: Studies Suggest Safety Ahead Of Lipocine's Oral Testosterone PDUFA

Executive Summary

While Lipocine Inc. is at the nail-biting stage of development for its oral testosterone Tlando (LPCN 1021) – awaiting a US FDA approval decision – urologists continue to study testosterone therapy to determine whether treatment of hypogonadal men is safe with appropriate monitoring.

You may also be interested in...



FDA imposes heart attack, stroke warnings on testosterones

The FDA on 3 March said it was imposing new warnings on the labeling of testosterone replacement therapies (TRTs), like AbbVie's $1bn drug AndroGel, about an increased risk of heart attack and stroke.

Lipocine SOARS on oral testosterone data despite FDA concerns

Top-line results from the pivotal Phase III SOAR trial of Lipocine's oral testosterone product LPCN 1021 in hypogonadal men with low testosterone (Low T) show that it met its primary endpoint of getting serum hormone levels back to normal. Lipocine expects to file a new drug application (NDA) with the US FDA in the second half of 2015.

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel